{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:57Z","timestamp":1790484357033,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00228-019-02743-9","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T22:02:41Z","timestamp":1567116161000},"page":"1705-1711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug-induced osteoporosis\/osteomalacia: analysis in the French and Spanish pharmacovigilance databases"],"prefix":"10.1007","volume":"75","author":[{"given":"Quentin","family":"Dardonville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Salguiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chebane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2743_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10067-010-1587-z","volume":"30","author":"L Gifre","year":"2011","unstructured":"Gifre L, Peris P, Monegal A, Martinez de Osaba MJ, Alvarez L, Guanabens N (2011) Osteomalacia revisited. A report on 28 cases. Clin Rheumatol 30:639\u2013645","journal-title":"Clin Rheumatol"},{"key":"2743_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","volume":"137","author":"C Cooper","year":"1993","unstructured":"Cooper C, Atkinson EJ, Jacobsen SJ, O\u2019Fallon WM, Melton LJ (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001\u20131005","journal-title":"Am J Epidemiol"},{"key":"2743_CR3","doi-asserted-by":"publisher","first-page":"505S","DOI":"10.1016\/8756-3282(95)00258-4","volume":"17","author":"BL Riggs","year":"1995","unstructured":"Riggs BL, Melton LJ (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:505S\u2013511S","journal-title":"Bone"},{"key":"2743_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.berh.2009.09.006","volume":"23","author":"C Kok","year":"2009","unstructured":"Kok C, Sambrook PN (2009) Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract Res Clin. Rheumatol 23:769\u2013779","journal-title":"Best Pract Res Clin. Rheumatol"},{"key":"2743_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00002018-200730010-00004","volume":"30","author":"B Bannwarth","year":"2007","unstructured":"Bannwarth B (2007) Drug-induced musculoskeletal disorders. Drug Saf 30:27\u201346","journal-title":"Drug Saf"},{"key":"2743_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4065\/mcp.2010.0636","volume":"86","author":"CJ Davidge Pitts","year":"2011","unstructured":"Davidge Pitts CJ, Kearns AE (2011) Update on medications with adverse skeletal effects. Mayo Clin Proc Mayo Clin 86:338\u2013343","journal-title":"Mayo Clin Proc Mayo Clin"},{"key":"2743_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","volume":"123","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877\u2013884","journal-title":"Am J Med"},{"key":"2743_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1759720X14546350","volume":"6","author":"P Keshav","year":"2014","unstructured":"Keshav P, Gona A, Humphrey MB (2014) Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskel Dis 6:185\u2013202","journal-title":"Ther Adv Musculoskel Dis"},{"key":"2743_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.therap.2016.02.029","volume":"71","author":"T Vial","year":"2016","unstructured":"Vial T (2016) French pharmacovigilance. Missions, organization and perspectives. Therapie 71:143\u2013150","journal-title":"Therapie"},{"key":"2743_CR10","unstructured":"Manso G (2010) La situaci\u00f3n actual del Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de uso Humano. En: Manso G, Hidalgo A, Carvajal A, de Abajo FJ, coordinadores. Los primeros 25 a\u00f1os del Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano. Oviedo: Universidad de Oviedo; P.19\u201323. Accessed 04\/04\/2019. Available at: \nhttps:\/\/www.unioviedo.es\/gaife\/documentos\/libro25aniversario\/Capitulos\/Capitulo_01.pdf"},{"key":"2743_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","volume":"71","author":"G Miremont-Salam\u00e9","year":"2016","unstructured":"Miremont-Salam\u00e9 G, Th\u00e9ophile H, Haramburu F, B\u00e9gaud B (2016) Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie 71:179\u2013186","journal-title":"Therapie"},{"key":"2743_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"2743_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"DEG Brown","year":"1999","unstructured":"Brown DEG, Wood L, Wood S (1999) The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 20:109\u2013117","journal-title":"Drug Saf"},{"key":"2743_CR14","first-page":"646","volume":"81","author":"AD Woolf","year":"2003","unstructured":"Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646\u2013656","journal-title":"Bull World Health Organ"},{"key":"2743_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2005.20.8.1486","volume":"20","author":"TP Van Staa","year":"2005","unstructured":"Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2005) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 20:1486\u20131493","journal-title":"J Bone Miner Res"},{"key":"2743_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00002018-200629020-00004","volume":"29","author":"A Carvajal","year":"2006","unstructured":"Carvajal A, Macias D, S\u00e1inz M, Ortega S, Mart\u00edn Arias LH, Velasco A, Bagheri H, Lapeyre-Mestre M, Montastruc JL (2006) HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf 29:143\u2013149","journal-title":"Drug Saf"},{"key":"2743_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/JCP.0000000000000094","volume":"34","author":"F Montastruc","year":"2014","unstructured":"Montastruc F, Scotto S, Vaz IR, Guerra LN, Escudero A, S\u00e1inz M, Falomir T, Bagheri H, Herdeiro MT, Venegoni M, Montastruc JL, Carvajal A (2014) Hepatotoxicity related to agomelatine and other new antidepressants: a case\/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems. J Clin Psychopharmacol 34:327\u2013330","journal-title":"J Clin Psychopharmacol"},{"key":"2743_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14740338.2018.1524868","volume":"17","author":"KD Nguyen","year":"2018","unstructured":"Nguyen KD, Bagheri B, Bagheri H (2018) Drug-induced bone loss: a major safety concern in Europe. Expert Opin Drug Saf 17:1005\u20131014","journal-title":"Expert Opin Drug Saf"},{"key":"2743_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bone.2009.07.083","volume":"46","author":"EM Haney","year":"2010","unstructured":"Haney EM, Warden SJ, Bliziotes MM (2010) Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management. Bone 46:13\u201317","journal-title":"Bone"},{"key":"2743_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S8756-3282(01)00593-2","volume":"29","author":"MM Bliziotes","year":"2001","unstructured":"Bliziotes MM, Eshleman A, Zhang X, Wiren K (2001) Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477\u2013486","journal-title":"Bone"},{"key":"2743_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1210\/en.2004-1259","volume":"146","author":"SJ Warden","year":"2005","unstructured":"Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685\u2013693","journal-title":"Endocrinology"},{"key":"2743_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/jbmr.3045","volume":"32","author":"V Bradaschia-Correa","year":"2017","unstructured":"Bradaschia-Correa V, Josephson AM, Mehta D, Mizrahi M, Neibart SS, Liu C, Kennedy OD, Castillo AB, Egol KA, Leucht P (2017) The selective serotonin reuptake inhibitor fluoxetine directly inhibits osteoblast differentiation and mineralization during fracture healing in mice. J Bone Miner Res 32:821\u2013833","journal-title":"J Bone Miner Res"},{"key":"2743_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","volume":"135","author":"VK Yadav","year":"2008","unstructured":"Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Sch\u00fctz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G (2008) LRP5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825\u2013837","journal-title":"Cell"},{"key":"2743_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.phrs.2018.07.018","volume":"140","author":"B Lavoie","year":"2019","unstructured":"Lavoie B, Roberts JA, Haag MM, Spohn SN, Margolis KG, Sharkey KA, Lian JB, Mawe GM (2019) Gut-derived serotonin contributes to bone deficits in colitis. Pharmacol Res 140:75\u201384","journal-title":"Pharmacol Res"},{"key":"2743_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-319-66653-2_3","volume":"1033","author":"B Lavoie","year":"2017","unstructured":"Lavoie B, Lian JB, Mawe GM (2017) Regulation of bone metabolism by serotonin. Adv Exp Med Biol 1033:35\u201346","journal-title":"Adv Exp Med Biol"},{"key":"2743_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.9740\/mhc.2019.01.006","volume":"9","author":"J Weaver","year":"2019","unstructured":"Weaver J, Kawsky J, Corboy A (2019) Antipsychotic use and fracture risk: an evaluation of incidence at a Veterans Affairs Medical Center. Ment Health Clin 9:6\u201311","journal-title":"Ment Health Clin"},{"key":"2743_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00198-018-4788-y","volume":"30","author":"TN Poly","year":"2019","unstructured":"Poly TN, Islam MM, Yang HC, Wu CC, Li YJ (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 30:103\u2013114","journal-title":"Osteoporos Int"},{"key":"2743_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"B Zhou","year":"2016","unstructured":"Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 27:339\u2013347","journal-title":"Osteoporos Int"},{"key":"2743_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.lfs.2018.12.058","volume":"218","author":"J Liu","year":"2019","unstructured":"Liu J, Li X, Fan L, Yang J, Wang J, Sun J, Wang Z (2019) Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci 218:213\u2013223","journal-title":"Life Sci"},{"key":"2743_CR30","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00198-018-4697-0","volume":"29","author":"JC Munson","year":"2018","unstructured":"Munson JC, Bynum JPW, Bell JE, McDonough C, Wang Q, Tosteson T, Tosteson ANA (2018) Impact of prescription drugs on second fragility fractures among US Medicare patients. Osteoporos Int 29:2771\u20132779","journal-title":"Osteoporos Int"},{"key":"2743_CR31","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00296-018-4142-x","volume":"38","author":"S Hussain","year":"2018","unstructured":"Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK (2018) Proton pump inhibitors\u2019 use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int 38:1999\u20132014","journal-title":"Rheumatol Int"},{"key":"2743_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1874325001711010777","volume":"21","author":"AN Ahmad","year":"2017","unstructured":"Ahmad AN, Ahmad SN, Ahmad N (2017) HIV infection and bone abnormalities. Open Orthop J 21:777\u2013784","journal-title":"Open Orthop J"},{"key":"2743_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bone.2016.09.017","volume":"93","author":"Z Wei","year":"2016","unstructured":"Wei Z, He JW, Fu WZ, Zhang ZL (2016) Osteomalacia induced by long-term low-dose adefovir dipivoxil: clinical characteristics and genetic predictors. Bone. 93:97\u2013103","journal-title":"Bone."},{"key":"2743_CR34","doi-asserted-by":"publisher","first-page":"bcr2013008674","DOI":"10.1136\/bcr-2013-008674","volume":"2013","author":"JM Lucey","year":"2013","unstructured":"Lucey JM, Hsu P, Ziegler JB (2013) Tenofovir-related Fanconi\u2019s syndrome and osteomalacia in a teenager with HIV. BMJ Case Rep pii 2013:bcr2013008674. \nhttps:\/\/doi.org\/10.1136\/bcr-2013-008674","journal-title":"BMJ Case Rep pii"},{"key":"2743_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jbspin.2016.04.004","volume":"84","author":"N Mehsen-C\u00eatre","year":"2017","unstructured":"Mehsen-C\u00eatre N, Cazanave C (2017) Osteoarticular manifestations associated with HIV infection. Joint Bone spine 84:29\u201333","journal-title":"Joint Bone spine"},{"key":"2743_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/17512433.2016.1123617","volume":"9","author":"SA Hamed","year":"2016","unstructured":"Hamed SA (2016) Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs. Expert Rev Clin Pharmacol 9:267\u2013286","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2743_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385\u2013396","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02743-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:23:15Z","timestamp":1598570595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2743"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02743-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}